BR0016092A - Compound, use of a compound kit for hormonal contraception in a male, and method of treatment - Google Patents
Compound, use of a compound kit for hormonal contraception in a male, and method of treatmentInfo
- Publication number
- BR0016092A BR0016092A BR0016092-0A BR0016092A BR0016092A BR 0016092 A BR0016092 A BR 0016092A BR 0016092 A BR0016092 A BR 0016092A BR 0016092 A BR0016092 A BR 0016092A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- male
- treatment
- kit
- hormonal contraception
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
"COMPOSTO, USO DE UM COMPOSTO KIT PARA CONTRACEPçãO HORMONAL EM UM MACHO, E, MéTODO DE TRATAMENTO". A invenção descrita refere-se à verificação inesperada de esteróides inéditos que são caracterizados por um anel 14<225>-15<225>-ciclopropano e um grupo hidroximetila em 17<244>. Verificou-se que estes esteróides de acordo com a invenção têm em comum uma atividade androgênica. Eles podem ser usados para a preparação de um agente para contracepção masculina, e também para a preparação de um medicamento para o tratamento de insuficiência de androgênio."COMPOUND, USE OF A COMPOUND KIT FOR HORMONAL CONTRACEPTION IN A MALE, AND, TREATMENT METHOD". The invention described relates to the unexpected verification of unpublished steroids that are characterized by a 14 <225> -15 <225> -cyclopropane ring and a hydroxymethyl group at 17 <244>. These steroids according to the invention have been found to have an androgenic activity in common. They can be used for the preparation of an agent for male contraception, and also for the preparation of a drug for the treatment of androgen insufficiency.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL99204080 | 1999-12-02 | ||
PCT/EP2000/012009 WO2001040255A2 (en) | 1999-12-02 | 2000-11-29 | 14,15-beta-methylene substituted androgens |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0016092A true BR0016092A (en) | 2002-07-30 |
Family
ID=19877249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0016092-0A BR0016092A (en) | 1999-12-02 | 2000-11-29 | Compound, use of a compound kit for hormonal contraception in a male, and method of treatment |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR100730010B1 (en) |
BR (1) | BR0016092A (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3086027A (en) | 1960-01-22 | 1963-04-16 | Lilly Co Eli | 19-nor-4, 9(10)-steroids and process |
IE60780B1 (en) * | 1987-01-23 | 1994-08-10 | Akzo Nv | New 11-aryl steroid derivatives |
DE19537626A1 (en) * | 1995-10-10 | 1997-04-17 | Jenapharm Gmbh | Steroids with a 14, 15 methylene group |
-
2000
- 2000-11-29 KR KR1020027007002A patent/KR100730010B1/en not_active IP Right Cessation
- 2000-11-29 BR BR0016092-0A patent/BR0016092A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20030024658A (en) | 2003-03-26 |
KR100730010B1 (en) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT199700009AA (en) | COMBINED THERAPY FOR OSTEOPOROSIS | |
AR022008A1 (en) | A COMPOSITION OF CONTROLLED GALANTAMINE RELEASE, A PROCESS FOR THE PREPARATION OF THE SAME, AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
ES2174629T3 (en) | 14,15-CYCLOPROPAN-STEROIDS OF THE 19-NOR-ANDROSTAN SERIES, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THESE COMPOUNDS. | |
ES2174920T3 (en) | COMBINATION PRODUCT FOR CONTRACEPTION CONTAINING PROGESTERONE ANTAGONIST AGENTS AND A GESTAGEN AGENT. | |
CR7420A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ONE OR VARIOUS STEROIDS, ONE OR VARIOUS COMPONENTS OF TETRAHIIDROPHOLATES AND VITAMIN B12 | |
HUP0302881A2 (en) | Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid | |
NZ333380A (en) | 6-O-methylerythromycin A crystal form I (clarithromycin) and preparation thereof | |
BR9404330A (en) | Device for mixing a pharmaceutical composition with another agent, process for preparing a pharmaceutical preparation by mixing a pharmaceutical composition with an agent, and process for the oral application of a pharmaceutical preparation. | |
HUP0104718A3 (en) | Micronized eplerenone compositions, process for their preparation and use thereof for the preparation of pharmaceutical compositions | |
KR970706001A (en) | PROCESS OF MAKING DOSAGE UNITS BY WET GRANULATION BY WET-GRANULATION | |
HUP0202537A2 (en) | A vaccine composition and method of using the same | |
BR0107667A (en) | Crystal linezolid compound which is pharmaceutically useful as an antibacterial agent and method of preparing it | |
DK1051159T3 (en) | Solid pharmaceutical preparations containing spleen fosin for oral administration in the treatment of leishmaniasis | |
GB9422990D0 (en) | Immunogenic compositions | |
WO2001040255A3 (en) | 14,15-beta-methylene substituted androgens | |
BR0010983A (en) | Preparations for the application of anti-inflammatory agents | |
TR200101766T2 (en) | Clathrates of dehydroepiandrosterone and corresponding compositions | |
BR0005392A (en) | Dhea composition and process | |
BR0016092A (en) | Compound, use of a compound kit for hormonal contraception in a male, and method of treatment | |
ATE160573T1 (en) | 1,3.5 (10) - ESTRATRIENIC DERIVATIVES WITH ORAL ACTION | |
TR200200683T2 (en) | Oral controlled release formulations. | |
HUP9904049A2 (en) | Growth hormone component and bone anti-resorptive agent in cyclic(coherence)treatment of osteoporosis | |
AR003001A1 (en) | PHARMACEUTICAL COMPOSITION STIMULATING OSTEOGENESIS. | |
BR9814136A (en) | Contraceptive set, manufacturing processes and bleeding treatment, uses of anti-progestin, progestin and anti-progestin, and a compound. | |
BR0213466A (en) | Use of (11beta, 17beta) -11- (1,3-benzodioxol-s-yl) -17-hydroxy-17- (1-propynyl) estra-4,9-dien-3-one, pharmaceutical preparation, and, Method for treating a patient suffering from severe depressive disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2142 DE 24/01/2012. |